Article 1 to 10 out of 24 for "Paclitaxel"
Ordered by
relevance
alphabet
date
Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients
(04 Sep 2008)
using intravenous administration of REOLYSIN(R) in combination with paclitaxel ... intravenously with paclitaxel and carboplatin every 3 weeks. Patients will receive four to six cycles of paclitaxel and carboplatin in conjunction with REOLYSIN(R...
Slipping through cell walls, nanotubes deliver high-potency punch to cancer tumors in mice
(18 Aug 2008)
worked with paclitaxel , a widely used cancer chemotherapy drug, which... of treatment, tumors in the mice treated with the paclitaxel -bearing nanotubes were... vehicles when the researchers attached the paclitaxel to the tips of the branches...
GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes
(17 Jun 2008)
to a taxane, including docetaxel (TaxotereŽ) and paclitaxel (TaxolŽ). The term...
Oncolytics Biotech Announces U.K. Phase II Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin
(16 May 2008)
intravenous administration of REOLYSIN(R) in combination with paclitaxel ... I dose escalation trial of REOLYSIN(R) in combination with paclitaxel ...) given intravenously in combination with a standard dosage of paclitaxel ...
Antisoma announces start of phase III lung cancer trial of ASA404
(14 Apr 2008)
Initiation triggers USD 25 million milestone payment from Novartis
either ASA404 1800 mg/m2 plus chemotherapy (carboplatin/paclitaxel ) or a placebo plus chemotherapy (carboplatin/paclitaxel ) as a control. The primary endpoint...
UCB: Phase II results for CDP791 in non-small cell lung cancer support further clinical development
(01 Apr 2008)
UCB announced first results of its phase II exploratory study of CDP791, a specific VEGFR-2/KDR inhibitor, in combination with carboplatin and paclitaxel chemotherapy in first line non-small cell lung cancer (NSCLC). Positive improvements...
Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel
(28 Aug 2007)
Genentech, Inc. announced that the company resubmitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for AvastinŽ (bevacizumab), in combination with paclitaxel chemotherapy...
ABRAXANE demonstrates longer progression-free survival versus Taxotere in the treatment of first-line metastatic breast cancer
(05 Jun 2007)
ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles...) for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound (nab(TM)) paclitaxel ) received approval in June 2006 from...
MediGene Obtains European Patent on EndoTAG(TM)-1
(20 Feb 2007)
" tumors. EndoTAG(TM)-1 combines the established active substance Paclitaxel ...
TopoTarget and CuraGen Initiate NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer
(16 Nov 2006)
, including 5-fluorouracil (5-FU), carboplatin, paclitaxel , cis-retinoic acid...
Additional information matching your search term
Additional information was found matching your search for "Paclitaxel" .